

**DUR Committee**  
January 20, 2012 Minutes

**Members Present:**

Robert Carlson, M.D. Telephonic  
William McCormick, Pharm.D.  
Dharna Begich, Pharm.D.  
Mary-Beth Gardner, ANP  
Chad Hope, Pharm.D. (DHSS)  
Julie Pritchard, Pharm.D. (Magellan)  
C.J. Kim, R.Ph (DHSS)

**Members Absent:**

John Pappenheim, M.D.  
Jeff Demain, M.D.

- Meeting started at 1:00pm and roll call.
- Informed committee Dr. Jeff Demain submitted letter of resignation.
- Review of minutes from previous meeting.
- Review agenda for additions or comments.

**ProDUR**

- Proposed prior authorizations:
  - **Vancocin** was discussed for PA, passed unanimously.
  - **Xifaxan** was discussed for PA, passed unanimously with diagnoses of hepatic encephalopathy to be grandfathered 90 days. Julie will help to code with Magellan.
  - **Zyvox** was discussed and criteria modified to delete line one and replace with new wording. “Zyvox not to be used as empiric or first-line treatment.” After new wording, committee approved unanimously.
  - **Intuniv** proposed quantity limits for 1mg, 2mg, 3mg and 4mg for quantities no more thirty and dosing for greater than 4mg per day require prior authorization, passed unanimously.
  - **Xanax XR** proposed quantity limits for 0.5mg, 1mg, 2mg, and 3mg for quantities no more thirty for the 0.5mg and 1mg and no more than sixty for the 2mg and 3mg and dosing for greater than 6mg per day require prior authorization, passed unanimously.
  - **Early Refill Edits** proposed 7 days early refill with a ‘lookback’ of 120 days, passed unanimously. Medicaid will monitor for input and can be revised as necessary.
- Review of New Prescription Medications (medications that have been on the Interim Prior Authorization for a minimum of six months):
  - Mononine, Vitafol-One, Nulojix and OB Complete 400 to be removed, passed unanimously.
  - Committee voted to keep Durasal on PA, passed unanimously.
  - The remaining ‘No Action – leave under current PA’, passed unanimously.
  - Revised PA criteria for Incivek and Victrelis, passed unanimously.

**Retrospective DUR**

- Discuss review criteria
- **Retrospective DUR** (simvastatin dose greater than equal 80mg/day).
  - The profiles were discussed and evaluated for intervention letters to be sent out to the providers.
  - Based on the criteria, most providers will get letters. Some providers will receive polypharmacy, polyproviders and other possible drug-drug interactions.
- Committee wanted to be to reach out to providers regarding the dosing adjustments with potential drug-drug interactions and for simvastatin. Add a portion on the response letter to how to possibly get the information or a website that addresses the new changes. (Julie and CJ will work on getting the information added to the response information).
- From P&T meeting, suggested review topical analgesics.
- Next meeting is scheduled for February 17, 2012 and location TBD.
- Meeting adjourned 3:00pm.